MBAM
LPCN icon

Mink Brook Asset Management’s Lipocine LPCN Stock Holding History

Mink Brook Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$534K Buy
+66,812
New +$582K 0.3% 40

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Mink Brook Asset Management's LPCN Position: Q1 2026 in Review

Mink Brook Asset Management opened a new position in Lipocine (LPCN) in Q1 2026: 66,812 shares worth $534K. The stake represents 0.3% of the portfolio and ranks #40 among its holdings.

47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Mink Brook Asset Management held 66,812 shares of Lipocine worth $534K as of Q1 2026.
  • Lipocine was a new Mink Brook Asset Management position in Q1 2026.
  • Lipocine made up 0.3% of Mink Brook Asset Management's portfolio in Q1 2026, its #40 holding.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Mink Brook Asset Management's 13F filing for Q1 2026, filed 1 Apr 2026.